Latest Proteasome inhibitor Stories
Compounds that kill dormant pathogen while sparing human cells could lead to new drugs.
SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.
Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma Patients - Proteolix Expands Trial ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc.
Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc.
Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc.
SOUTH SAN FRANCISCO, Calif., April 16 /PRNewswire/ -- Proteolix, Inc. today announced the appointment of Craig C.
SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the appointment of John A.
SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.
SOUTH SAN FRANCISCO, Oct.
The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and Europe access to drugs similar to what is available to patients in the United States.
- A volcanic mudflow.